Contrasting 10x Genomics (NASDAQ:TXG) and Mitesco (OTCMKTS:MITI)

Mitesco (OTCMKTS:MITI) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Earnings & Valuation

This table compares Mitesco and 10x Genomics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mitesco	$40,000.00	61.78	$500,000.00	($0.33)	-0.28
10x Genomics	$642.82 million	8.64	-$43.54 million	($0.17)	-257.29

Mitesco has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Mitesco, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Mitesco and 10x Genomics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mitesco	0	0	0	0	0.00
10x Genomics	1	10	4	0	2.20

10x Genomics has a consensus target price of $32.08, indicating a potential downside of 26.65%. Given 10x Genomics’ stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Mitesco.

Profitability

This table compares Mitesco and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mitesco	N/A	-2.18%	-2,982.65%
10x Genomics	-3.55%	-2.86%	-2.23%

Insider & Institutional Ownership

0.0% of Mitesco shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 4.9% of Mitesco shares are owned by insiders. Comparatively, 8.8% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Mitesco has a beta of 4.95, suggesting that its stock price is 395% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.

Summary

10x Genomics beats Mitesco on 8 of the 14 factors compared between the two stocks.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.